Drug Profile
Anti-CD19 CAR-T cell therapy - Bioceltech Therapeutics
Alternative Names: Anti CD19 chimeric antigen receptor T cell therapy- Bioceltech TherapeuticsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bioceltech Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral)
- 01 Jun 2018 Clinical trials in Precursor B cell lymphoblastic leukaemia-lymphoma (In children, In adolescents, In adults, In the elderly, Second line therapy or greater) in China (Parenteral)